Chicago and Nashville, USA – January 6, 2019 – GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before... Read more
Basel, 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in children European Medicines Agency PRIME... Read more
10 DEC 2018 | DARMSTADT, GERMANY genOway to acquire exclusive rights to Merck’s foundational genome-editing patents to produce, sell rodent models New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, announced that its life... Read more
Basel, 07 December 2018 FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no... Read more
Basel, 05 December 2018 FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for... Read more
Basel, 21 November 2018 Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for... Read more
HILLERØD, November 19, 2018 – Today, FOSS awarded Professor Robert David Hall the Nils Foss Excellence Prize for his pioneering research in plant metabolomics – the chemical fingerprint of plant cells. The award consists of 100,000 euro and this year in particular, it carries special meaning. FOSS, the world’s leading supplier of analytical solutions... Read more
RYE BROOK, N.Y.–(BUSINESS WIRE)–Nov. 19, 2018– Xylem Inc. (NYSE: XYL), a leading global water technology provider, has signed a Memorandum of Understanding (MoU) with Ethiopia’s Ministry of Water, Irrigation and Energy (MoWIE) for future cooperation to help advance water security in Ethiopia. The MoU was signed at an event in Ethiopia attended by Ethiopia’s Minister of Water, Irrigation and... Read more
Agilent Introduces Groundbreaking UV-Vis Spectrophotometer for Pharmaceutical, Biomedical, and Academic Laboratories Cary 3500 UV-Vis system can run multiple experiments simultaneously, boosting laboratory efficiency SANTA CLARA, Calif., November 1, 2018 Agilent Technologies Inc. (NYSE: A) today introduced the Cary 3500 UV-Vis system, an innovative spectrophotometer designed to help life science, pharma and biopharma research communities simplify... Read more
October 31, 2018 Spectro Scientific, one of the world’s largest suppliers of oil, fuel, and processed-water analysis instrumentation and software, has released a new generation of its field-proven FluidScan® mid-infrared spectrometer handheld oil analyzer. Patented FluidScan technology collects light transmitted through one drop of a fluid sample and registers the infrared absorption spectrum. The analyzer compares spectrum data to... Read more